Lynx1 Capital Management LP Immuno Gen, Inc. Transaction History

Lynx1 Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $4.86 Million - $8.89 Million	-1,543,259 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $2.5 Million - $4.39 Million	-586,272 Reduced 27.53%	1,543,259 $7.35 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $10.1 Million - $16 Million	2,129,531 New	2,129,531 $15.8 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.